Business & FinanceBreaking NewsBreakingLatest News
Dr Reddy's Receives Brazil Approval for Generic Ozempic
Sentiment: NeutralHigh Priority
What Happened?
Dr Reddy's Laboratories has gained regulatory approval in Brazil to market a generic version of Novo Nordisk's diabetes drug Ozempic. The drug will be available in 2 mg and 4 mg doses.
Key points
- Brazil has 16.6 million adults aged 20-79 living with diabetes.
- The National Health Surveillance Agency (ANVISA) authorized semaglutide for type 2 diabetes treatment.
- Dr Reddy's had previously faced a denial for this drug in April due to unmet regulatory requirements.
- The drug will be available in pre-filled injector pens.
- Dr Reddy's aims to launch the drug in Latin America and Africa soon.
Key insights
- The approval may lead to increased competition in the diabetes medication market in Brazil.
- Dr Reddy's could see significant revenue growth from this generic drug.
- The company's strategy includes expanding its presence in Latin America and Africa.
Why it matters
This approval could enhance access to diabetes treatment for millions in Brazil.
Entities
Dr Reddy's Laboratories· CompanyNovo Nordisk· CompanyBrazil· CountryANVISA· Organization
Source
Business Standard
